Literature DB >> 10797091

Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.

P H Chandrasekar1, J Cutright, E Manavathu.   

Abstract

We compared the efficacies of amphotericin B and voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. A susceptible isolate of Aspergillus fumigatus was used to produce the infection. Voriconazole-treated animals had significantly better survival and decreased fungal burden in the lungs as compared with controls. Although no statistical difference was seen between the efficacies of voriconazole and amphotericin B, a trend favouring voriconazole was noted. Thus, voriconazole, with its cidal activity, may be an attractive alternative to potentially toxic amphotericin B in the treatment of invasive pulmonary aspergillosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797091     DOI: 10.1093/jac/45.5.673

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

Review 1.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis.

Authors:  Carolina Serena; Félix Gilgado; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 3.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Efficacy of Voriconazole against Aspergillus fumigatus Infection Depends on Host Immune Function.

Authors:  Emily E Rosowski; Jiaye He; Jan Huisken; Nancy P Keller; Anna Huttenlocher
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

5.  MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex.

Authors:  Valentina Salas; F Javier Pastor; Deanna A Sutton; Enrique Calvo; Emilio Mayayo; Annette W Fothergill; Michael G Rinaldi; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

6.  Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.

Authors:  Wendy W J van de Sande; Ron A A Mathot; Marian T ten Kate; Wim van Vianen; Mehri Tavakol; Bart J A Rijnders; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

7.  Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.

Authors:  Joseph Meletiadis; Charalampos Antachopoulos; Theodouli Stergiopoulou; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

8.  Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs.

Authors:  Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Use of lung resection and voriconazole for successful treatment of invasive pulmonary Aspergillus ustus infection.

Authors:  A Azzola; J R Passweg; J M Habicht; L Bubendorf; M Tamm; A Gratwohl; G Eich
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

Review 10.  Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.

Authors:  Florence Ader; Anne-Lise Bienvenu; Blandine Rammaert; Saad Nseir
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.